Inventor · disambiguated record
Stephen E. Schneider
Also filed as: SCHNEIDER STEPHEN · SCHNEIDER STEPHEN E
11 granted patents·16 pending applications·201 citations·filing 1975–2025
90Inventor score
Files withMIND MEDICINE INC10PHARMACOSMOS HOLDING AS4G1 THERAPEUTICS INC3CEMPRA PHARMACEUTICALS INC2DOW CHEMICAL CO2
Top patents by PatentIndex Score
27 records- 0197US4020230AMicroporous polyethylene hollow fibers and process of preparing themDOW CHEMICAL CO·Filed 1975·Granted Apr 26, 1977·122 cites·4 claims
- 0295US12168666B2Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2021·Granted Dec 17, 2024·8 cites·27 claims
- 0395US10988479B1Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·15 cites·14 claims
- 0494US11708337B2Synthesis of 1,4-diazaspiro[5.5]undecan-3-oneG1 THERAPEUTICS INC·Filed 2021·Granted Jul 25, 2023·5 cites·26 claims
- 0593US12264135B2Synthesis of 1,4-diazaspiro[5.5]undecan-3-onePHARMACOSMOS HOLDING AS·Filed 2023·Granted Apr 1, 2025·3 cites·18 claims
- 0686US2025101030A1Morphic forms of trilaciclib and methods of manufacture thereofPHARMACOSMOS HOLDING AS·Filed 2024·Application pending·0 cites
- 0785US4115492AProcess for preparing microporous polyethylene hollow fibersDOW CHEMICAL CO·Filed 1977·Granted Sep 19, 1978·38 cites·8 claims
- 0884US7456251B2HIV fusion inhibitor peptides with improved biological propertiesTRIMERIS INC·Filed 2007·Granted Nov 25, 2008·10 cites·19 claims
- 0981US12497404B2Morphic forms of trilaciclib and methods of manufacture thereofPHARMACOSMOS HOLDING AS·Filed 2025·Granted Dec 16, 2025·0 cites·11 claims
- 1081US12479855B2Morphic forms of trilaciclib and methods of manufacture thereofPHARMACOSMOS HOLDING AS·Filed 2025·Granted Nov 25, 2025·0 cites·13 claims
- 1181US12097184B2Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2023·Granted Sep 24, 2024·0 cites·2 claims
- 1281US2025205196A1Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2024·Application pending·0 cites
- 1374US2022370413A1Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2022·Application pending·0 cites
- 1472US2023416219A1R-mdma crystal formsMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 1567US2025161268A1Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2025·Application pending·0 cites
- 1666US2025019359A1R-mdma crystal formsMIND MEDICINE INC·Filed 2024·Application pending·0 cites
- 1765US8034899B2HIV fusion inhibitor peptides with improved biological propertiesTRIMERIS INC·Filed 2008·Granted Oct 11, 2011·0 cites·64 claims
- 1863US2024010628A1Methods of manufacture of r-mdmaMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 1963US2022280482A1Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2022·Application pending·0 cites
- 2059US2021070797A1Processes for preparing fluoroketolidesTETARD INC·Filed 2020·Application pending·0 cites
- 2157US2023303572A118-mc salt formsMIND MEDICINE INC·Filed 2023·Application pending·0 cites
- 2255US2025161267A1Formulations of psilocin that have enhanced stabilityMIND MEDICINE INC·Filed 2025·Application pending·0 cites
- 2346US2010261876A1Novel methods of synthesis for therapeutic antiviral peptidesBRAY BRIAN L·Filed 2008·Application pending·0 cites
- 2443US2012040891A1Hiv fusion inhibitor peptides with improved biological propertiesDWYER JOHN J·Filed 2011·Application pending·0 cites
- 2542US2018044365A1Processes for preparing fluoroketolidesCEMPRA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2639US2006167220A1Methods and compositions for preparing peptides with excellent solubility characteristics in aqueous solution at physiological pHDAUER RICHARD·Filed 2005·Application pending·0 cites
- 2736US2018016226A14-azidobutylamines and processes for preparingCEMPRA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen E. Schneider files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →